Scrip's 2001 Yearbook - 17th Edition

Scrip's 2001 Yearbook � 17th Edition

Reference

People, Products and Financials

The 17th edition of Scrip's Yearbook contains three new sections, covering e-commerce activities in the pharmaceutical industry, a summary of a selection of the Scrip Reports published during 2000 and an overview of clinical trial results organised by therapeutic indication.

The new section on e-commerce includes highlights of website launches that have been mentioned in Scrip during 2000, as well as an article reviewing a study on pharmaceutical purchasing via the Internet. E-commerce activities by specific countries and pharmaceutical companies are also included in this section, which gives an overview of Internet-based developments within the pharmaceutical industry during 2000.

Summaries of a selection of Scrip Reports have been brought together to form another new section of the 2001 Yearbook. These summaries provide an insight into the subjects covered in each report and deal with a diverse range of subject areas including women's healthcare, advances in pain management, gastrointestinal disorders, DTC advertising and mergers and acquisitions.

The third new section of the 2001 Yearbook contains results from clinical trials that have been published or presented in 2000 and subsequently reported in Scrip. The section includes results of a study comparing simvastatin (Merck & Co's Zocor) with atorvastatin (Pfizer's Lipitor), a comparison of calcium blockers with antihypertensives and the results of Phase III trials with Takeda/Abbott's Uprima (apomorphine) for erectile dysfunction.

As with previous editions of the Yearbook, there are also sections on country markets, industry data and details of the activities of the top 30 pharmaceutical companies, as well as disease statistics in the therapeutic section and an industry overview. In addition, for each country mentioned in the Yearbook there is also a table of socio-demographic data, detailing the size of the country's population, birth and death rates, employment levels, literacy levels and access to safe water and healthcare.

The 2001 Yearbook also details two of the most significant events to occur within the pharmaceutical industry in 2000 � the merger of Pfizer and Warner-Lambert and the Glaxo Wellcome merger with SmithKline Beecham, which only just made it into the Yearbook with FDA approval in December. Following these mergers, Glaxo SmithKline is the world's leading pharmaceutical company, followed closely by the new Pfizer.

Pfizer and Warner-Lambert concluded their $90 billion merger on February 7th 2000, ending the three-way struggle with Warner-Lambert's original merger partner, American Home Products. The enlarged company, known as Pfizer, has expected annual revenues of about $28 billion (including $21 billion in pharmaceutical sales) and a market capitalisation of $230 billion. Revenues are expected to grow at an annual rate of 13% until 2003. Earnings growth is expected to increase by 25% annually until 2002, helped by the planned $1.6 billion cost savings, more than 60% of which should be achieved by 2001.

The deal headed off a court battle between Warner-Lambert and Pfizer over their agreement for the cholesterol-lowering product, Lipitor (atorvastatin). This was set to begin on February 14th and had been a driving force in the negotiations. The companies had sued and counter-sued each other, with Warner-Lambert contending that, by making a hostile bid, Pfizer jeopardised its rights to certain Lipitor profits.

The new Pfizer has six $1 billion dollar blockbuster products in its portfolio: Norvasc (amlodipine); Zoloft (sertraline); Zithromax (azithromycin); Diflucan (fluconazole); Celebrex (celecoxib), which Pfizer co-promotes with the product's originator, Searle; Viagra (sildenafil); and Lipitor, which is expected to produce $5 billion in sales in 2000.

In December 2000, FDA approval was finally granted for the merger between Glaxo Wellcome and SmithKline Beecham. The merged company will be a leader in four of the five main therapeutic categories: anti-infectives, CNS, respiratory, and alimentary and metabolic diseases � together these sectors represent close to 50% of the global pharmaceutical market. It will also have the leading position in the vaccines market and a strong consumer healthcare business. The companies' consumer divisions had 1998 sales of �2.4 billion and ranked second in the world in over-the-counter medicines and fourth in oral healthcare.

In the area of drug discovery, Glaxo Wellcome is strong in combinatorial chemistry while SmithKline Beecham has established itself as the industry leader in the use of genomics in the discovery of new drug targets, having built on its pioneering collaboration with Human Genome Sciences, since 1993.

Another significant event which is included in the Yearbook is the sale of BASF's pharmaceutical division, Knoll, to Abbott. Only a year ago BASF gave its pharmaceuticals division two years to shape up, but the sale to Abbott for $6.9 billion in cash came as no great shock to the industry. BASF had ordered the pharma business to bring its earnings before interest and tax up from around 5% of sales to the level of peer companies (15�20%), but, in 1999, the unit only achieved earnings before special items of e175 million on sales of e2.5 billion. The sale is expected to be completed during the first quarter of 2001.

It had been rumoured that Eli Lilly, Bristol-Myers Squibb and Sanofi-Synth�labo were all interested in acquiring BASF Pharma. These companies would have been tempted by the market potential of BASF Pharma's anti-TNF antibody, D2E7, which is in Phase III trials for rheumatoid arthritis and has been tipped by analysts as being capable of achieving peak sales of e500 million.

In the area of research, the major event of 2000 was the completion of the first draft of the sequenced human genome. The future implications of this achievement are still the subject of great debate, along with the emotive issue of cloning. However, with the withdrawal of PPL Therapeutics from the area of xenotransplantation, the excitement surrounding the future role of genomics in the pharmaceutical industry does seem to be waning slightly.

2000 was very much a year of consolidation for the pharmaceutical industry, which raised a few questions about the benefits to R&D of this merger frenzy. The answer as to whether a doubled effort and greatly increased budget can produce the blockbusters, or even the megablockbusters, frantically sought by the major players in the industry may be answered in 2001.

Scrip's Yearbook 2001 is an invaluable addition to any personal, company or business library. It is a one-stop source of facts, data and statistics on pharmaceutical markets, products and companies worldwide. This easy-to-use guide will enable readers to: have an instant and informed view of the pharmaceutical industry; understand market trends and estimate market sizes; analyse new products and review recent developments and assess competitors and their products.

In a revised format, this 17th Edition is divided into six key sections:

Scrip Reports. A synopsis covering the major themes and events of the past year, and key findings, covered in Scrip Reports publications.

Financial and other information about 30 of the leading companies worldwide as listed by Scrip's 2000 Pharmaceutical Company League Tables.

Invaluable R&D information on late-stage drug trials for the treatment of major diseases, listed by therapeutic indication.

Valuable industry and market data on individual countries and regions.

Therapeutic section, containing details of a wide variety of diseases, as well as their various treatment methods.

Country data, including population size, birth rate, healthcare spending and major diseases in each country profiled.

Published: January 2001
Ref: BS1091E
Pages: 468
Price: £450/$945/¥108,000

For further information about this report, please contact our Customer Helpdesk on:
Tel: +44 (0)20 8332 8965 / 66
Fax: +44 (0)20 8332 8992
E-mail: [email protected]

CONTENTS
LIST OF TABLES
INTRODUCTION

SECTION 1 SCRIP REPORTS
1.1 Developments in the management of diabetes
1.1.1 Marketed drugs for the management of diabetes and its complications
1.1.2 Drugs in development for the management of diabetes and its complications
1.1.3 Diabetes market information and epidemiology
1.2 Direct-To-Consumer Advertising: Changing the Face of Pharmaceutical Marketing
1.3 Gastrointestinal Disorders: New Therapies for the New Millennium
1.4 Scrip's Complete Guide to Men's Healthcare
1.5 Orphan Drugs: Medical Breakthroughs and Commercial Opportunities
1.6 Advances in Pain Management
1.7 Pharmaceutical and Biotechnology Mergers and Acquisitions: The glass ceiling
1.8 Pharmaceutical Pricing, Sales and Distribution in Japan
1.9 Real Options Evaluation in Pharmaceutical R&D: a New Approach to Financial Project Evaluation
1.10 Scrip's Guide to Successful Pharmaceutical Marketing
1.11 The Impact of E-Commerce on the Pharmaceutical Industry
1.12 Pharmaceuticals: the New Management Agenda for the 21st Century
1.13 Scrip's Complete Guide to Women's Healthcare

SECTION 2 INDUSTRY OVERVIEW
2.1 Global pharmaceutical market, April 1999�March 2000
2.2 Pharmaceutical sales by leading therapeutic categories, 1999/2000
2.3 World pharmaceutical sales, year to June 2000
2.4 Market value of biotech companies, 1999�2000
2.5 Market share prediction post Glaxo Wellcome/SmithKline Beecham merger
2.6 Sales in leading therapeutic classes, 1999
2.7 Sales of top global products, 1999
2.8 IT market for life sciences
2.9 Global OTC sales, 1999
2.10 Value of global nasal corticosteroid market
2.11 US managed care pharmaceutical company rankings, Autumn 1999
2.12 US managed care pharmaceutical company rankings, Spring 2000
2.13 Pharmaceutical company status by US physician opinion
2.14 Pharmaceutical company rankings among US and European global organisations
2.15 New product development growth, 2000�2005
2.16 New chemical entity production, 2000�2008
2.17 Pharmaceutical industry lobbying expenditure
2.18 Differences between drug prices in developed and developing countries
2.19 Changes in European OTC distribution
2.20 International pharmaceutical price comparisons
2.21 Comparison of patent application costs
2.22 Genomics deals
2.23 Worldwide R&D investment
2.24 Pharmaceutical company league table (top 30)
2.25 World Health Report 2000
2.25.1 Health systems: improving performance
2.26 Human Genome Project

SECTION 3 COMPANIES
3.1 Abbott
3.1.1 Abbott pharmaceutical sales, 1999
3.1.2 First half and second quarter results, 2000
3.1.3 Third quarter earnings, 2000
3.1.4 Purchase of BASF Pharma (Knoll)
3.2 Akzo Nobel
3.2.1 Akzo Nobel 2nd quarter 2000 results
3.2.2 Akzo Nobel's product portfolio
3.3 American Home Products
3.3.1 American Home Products sales, 1999
3.3.2 American Home Products' 1st quarter 2000 results
3.3.3 Second quarter, first half 2000 results
3.4 Amgen
3.4.1 Amgen sales, 1999
3.4.2 Amgen R&D expenditure, 1999
3.5 AstraZeneca
3.5.1 AstraZeneca sales, 1999
3.5.2 Losec sales, 1999
3.5.3 Seloken ZOC sales, 1999
3.6 Aventis
3.6.1 Aventis Pharma sales, 1999
3.6.2 Aventis financial data, 1999
3.6.3 Aventis Pharma key markets, 1999
3.6.4 Aventis Thai sales forecast, 2000
3.7 Bayer
3.7.1 Bayer healthcare sales, 1999
3.7.2 Bayer US sales, 1999
3.7.3 Bayer's pharmaceutical Japanese sales, 1999
3.8 Boehringer Ingelheim
3.8.1 Boehringer Ingelheim financial data, 1999
3.8.2 Sales at Nippon Boehringer Ingelheim, 1999
3.9 Bristol-Myers Squibb
3.9.1 Bristol-Myers Squibb pharmaceutical sales, 1999
3.10 Eisai
3.10.1 Eisai's sales, year ended March 2000
3.10.2 Eisai sales forecast, 2001�2006
3.10.3 Eisai's R&D pipeline
3.11 Eli Lilly
3.11.1 Eli Lilly sales, 1999
3.11.1.1 Prozac UK sales, 1998
3.11.1.2 Prozac tablet sales
3.11.2 Eli Lilly's late-stage development pipeline
3.11.2.1 Eli Lilly's new products
3.11.3 Lilly Japan
3.12 Fujisawa
3.12.1 Fujisawa sales, year ended March 2000
3.13 Glaxo SmithKline
3.13.1 Glaxo Wellcome and SmithKline Beecham merger
3.13.2 Glaxo SmithKline sales forecast
3.13.3 Research & development strength of Glaxo SmithKline
3.13.4 Patent analysis
3.13.5 Patent expirations
3.13.6 Glaxo SmithKline pro forma financial information
3.13.7 Glaxo Wellcome sales, 1999
3.13.8 SmithKline Beecham's pharmaceutical sales, 1999
3.14 Hoffman La-Roche
3.14.1 Roche sales, 1999
3.14.2 Nippon Roche sales, 1999
3.14.3 Xenical sales, 1999
3.15 Johnson & Johnson
3.15.1 Johnson & Johnson sales, 1999
3.15.2 Withdrawal of Prepulsid
3.16 Knoll
3.16.1 BASF pharma sales, 1999
3.16.2 Knoll Brazil sales, 1999
3.16.3 Sale of BASF Pharma to Abbott
3.17 Merck & Co
3.17.1 Merck & Co sales, 1999
3.17.2 Merck & Co vaccine internet site
3.17.3 Banyu Pharmaceutical
3.18 Merck KGaA
3.18.1 Merck KGaA sales, 1999
3.18.2 Merck KGaA generic sales, 1999
3.19 Novartis
3.19.1 Novartis sales, 1999
3.19.2 Novartis top product sales, 1999
3.19.3 Novartis's generic sales
3.19.4 Novartis US sales, 1999
3.20 Novo Nordisk
3.20.1 Novo Nordisk sales, 1999
3.21 Pfizer
3.21.1 Pfizer and Warner-Lambert merger
3.21.2 Pfizer/Warner-Lambert merger approval
3.21.3 US sales forecast for Pfizer's generic calcium antagonists, 1999
3.21.4 Pfizer sales, 1999
3.21.5 Pfizer Japanese sales, 1999
3.21.6 Warner-Lambert revenues, 1999
3.21.7 Lipitor sales forecast, 2004
3.22 Pharmacia
3.22.1 Pharmacia Corporation
3.22.2 Pharmacia & Upjohn pharmaceutical sales, 1999
3.22.3 Pharmacia & Upjohn sales, 1999
3.22.4 Pharmacia OTC global sales, 1999
3.22.5 Zyvox first market approval
3.22.6 Searle sales, 1999
3.23 Sankyo
3.23.1 Sankyo sales, year ended March 2000
3.24 Sanofi Synth�labo
3.24.1 Sanofi-Synth�labo sales, 1999
3.24.2 Sanofi-Synth�labo US sales, 1999
3.25 Schering AG
3.25.1 Schering AG sales, 1999
3.26 Schering-Plough
3.26.1 Schering-Plough sales, 1999
3.27 Shionogi
3.27.1 Sionogi prescription sales
3.27.2 Shionogi net profit forecast
3.28 Taisho
3.29 Takeda
3.29.1 Takeda pharmaceutical sales
3.29.2 Takeda sales and profit forecast, 2000/2001
3.30 Yamanouchi
3.30.1 Yamanouchi net sales and operating profit, 1999
3.30.2 Yamanouchi sales forecast, 2000
3.30.2.1 Yamanouchi amended sales forecast, 2000
3.30.3 US pipeline, genomics

SECTION 4 E-COMMERCE IN THE PHARMACEUTICAL INDUSTRY
4.1 Website launch highlights (as mentioned in Scrip)
4.1.1 SmithKline Beecham's vaccine website
4.1.2 Pharmabiz.com
4.1.3 Allcure.com
4.1.4 SafeMedication.com
4.1.5 European launch of Chemdex
4.1.6 RheumatologyWeb.com
4.1.7 YourDoctor.com
4.1.8 business-2-business e-marketplace
4.1.9 e-Lilly
4.1.10 Glaxo Wellcome's Japanese migraine website
4.2 Pharmaceutical purchasing via the Internet
4.3 E-commerce activities by country
4.3.1 Australia
4.3.1.1 New Australian code covers Internet
4.3.2 New Zealand
4.3.2.1 New Zealand closes Internet drug sales loophole
4.3.3 China
4.3.3.1 China bans Internet pharmaceutical trade
4.3.4 Europe
4.3.4.1 European pharmaceutical firms sceptical of eR&D
4.3.5 UK
4.3.5.1 UK Web pharmacy launched
4.3.5.2 High interest in e-Rx (electronic prescription) pilots in England
4.3.6 Turkey
4.3.6.1 Turkish Internet system speeds pharmacy reimbursement
4.3.7 United States
4.3.7.1 US acts on illegal Internet sales
4.3.7.2 Pharmacists launch 'safe' website
4.3.7.3 Rx.com enters joint venture to attract Latin American business
4.3.8 Brazil
4.3.8.1 New website for Brazil monitoring agency
4.4 Internet activities by company
4.4.1 Aventis
4.4.2 Institut Pasteur
4.4.3 Amgen
4.4.4 Bayer
4.4.5 BASF
4.4.6 Eli Lilly
4.4.7 PDxMed's point-of-care website
4.5 Therapeutic based websites
4.5.1 Diabetes websites launched

SECTION 5 COUNTRIES
AFRICA
5.1 Africa (General)
5.1.1 Pharma opportunities in North Africa
5.1.2 AIDS prevention expenditure in Africa, 1996
5.1.3 Decreasing prevalence of onchocerciasis in Africa, 1977�2000
5.1.4 Economic impact of malaria and HIV/AIDS
5.1.5 Prevalence of blindness in francophone Africa
5.1.6 WHO action in the Horn of Africa
5.1.7 WHO Vision 2020 programme in Africa
5.2 Botswana
5.2.1 Life expectancy in Botswana, 2010
5.3 Cameroon
5.3.1 Prevalence of HIV/AIDS in Cameroon
5.4 Democratic Republic of Congo
5.4.1 Restoration of state pharmaceutical lab
5.5 Egypt
5.5.1 Egyptian pharmaceutical sector
5.6 Ghana
5.6.1 Prevalence of meningitis in Ghana
5.7 Namibia
5.7.1 Supply of antiretroviral products for rape victims
5.8 Nigeria
5.8.1 Pharmaceutical manufacturing in Nigeria
5.9 Uganda
5.9.1 AIDS in Uganda
5.10 Zambia
5.10.1 Zambian pharmaceutical imports, 2000
AUSTRALASIA
5.11 Australia
5.11.1 Australian biotechnology revenues, 1999
5.11.2 Australian Pharmaceutical Benefits Scheme expenditure, 1999
5.11.3 Research funding in Australia, 2000
5.11.4 Australian Pharmaceutical Benefits Scheme expenditure, year to March 2000
5.11.5 Australian Pharmaceutical Benefits Scheme expenditure, year to June 2000
5.11.6 Incidence of strokes in Australia
5.11.7 Adverse drug reactions reported in Australia since 1972
5.11.8 Australian antidepressant use, 1990�1999
5.12 New Zealand
5.12.1 Pharmaceutical expenditure in New Zealand, 1998/99
5.12.2 New Zealand Internet pharmaceutical sales, 1999
5.12.3 New Zealand Internet regulations
5.12.4 Alendronate subsidies in New Zealand
5.12.5 New Zealand's Pharmaceutical Schedule expenditure, 1999�2000
5.12.6 Pharmaceutical expenditure, 1989�1999
5.12.7 New Zealand listings in 2000
5.12.8 Rates of disease in Maori's
CENTRAL AND EASTERN EUROPE
5.13 Bulgaria
5.13.1 Bulgarian pharmaceutical market, 1999
5.13.2 Antibiotic resistance in Bulgaria
5.14 Croatia
5.14.1 Drug shortages in Croatia, 2000
5.14.2 Croatian marketing authorisations
5.15 Czech Republic
5.15.1 Czech pharmaceutical market, 1999
5.15.2 Czech pharma deficit
5.16 Hungary
5.16.1 Hungarian generics market, 2000
5.16.2 Hungarian National Health Fund budget, 2000
5.16.3 Hungarian pharmaceutical market, 1999
5.16.4 Hungarian pharmaceutical sales by company, 1999
5.16.5 Hungarian expenditure on 100% reimbursed products, 1999
5.16.6 Hungarian healthcare expenditure, 2001�2002
5.17 Poland
5.17.1 Wholesale mark-up on imported pharmaceuticals in Poland
5.17.2 Polish healthcare insurance system
5.17.3 Per capita expenditure in Poland
5.18 Slovakia
5.18.1 Slovak market growth, 1999
5.18.2 Healthcare expenditure
EUROPE
5.19 Europe General
5.19.1 Generic pharmaceutical market share in Europe, 2004
5.19.2 Nordic pharmaceutical market growth 1999�2000
5.19.3 Antibiotic usage in Europe
5.19.4 NHS expenditure in comparison with European healthcare expenditure
5.19.5 European Agency for the Evaluation of Medicinal Products expenditure, 1998�1999
5.19.6 European pharmaceutical industry competitiveness enquiry
5.20 Belgium
5.20.1 Belgian pharmaceutical price-cuts
5.20.2 NSAID expenditure in Belgium
5.20.3 Incidence of resistant TB in Belgium
5.21 Denmark
5.21.1 Appetite suppressant usage in Denmark, 1999
5.22 Finland
5.22.1 Finnish pharmaceutical market, 1999
5.22.2 Wholesale pharmaceutical price growth, 1999
5.23 France
5.23.1 French non-prescription market turnover
5.23.2 French product market withdrawls, 1999
5.23.3 Generic market share in France
5.23.4 French generic market, 1999
5.23.5 French generic sales, 1999
5.23.6 Reimbursed pharmaceutical expenditure in France, 1998
5.23.7 Reimbursed pharmaceutical expenditure in France, 1999
5.23.8 Pharmaceutical sales, 1998�1999
5.23.9 Pharmaceutical exports, 2000 (6 months)
5.23.10 Pharmaceutical market, 1999
5.23.11 Antibiotic prescription levels in France
5.23.12 Incidence of osteoarthritis in France
5.23.13 Prevalence of HIV/AIDS in France
5.23.14 Levels of prescription medicine use during pregnancy in France
5.24 Germany
5.24.1 Pharmaceutical expenditure in Germany, 1999
5.24.2 German patent applications, 1999
5.25 Greece
5.25.1 Parallel trade in Greece
5.25.2 Greek private healthcare sector
5.25.3 Greek government pharmaceutical expenditure
5.26 Italy
5.26.1 Italian state medical expenditure, 1999�2000
5.26.2 Italian pharmaceutical expenditure, 1999
5.26.3 Italian pharmaceutical spending trends, 6 months 2000
5.26.4 Italian pharmaceutical expenditure forecast, 2000
5.26.5 Italian orphan indication list
5.26.6 Value of Italian pharmaceutical production, 1999
5.26.7 Italian biotechnology sector
5.26.8 Prevalence of Alzheimer's in Italy
5.27 Portugal
5.27.1 Portuguese generic pharmaceutical expenditure
5.27.2 Influenza vaccination rate in Portugal, 1999
5.27.3 Portuguese pharmaceutical industry levy
5.28 Spain
5.28.1 Spanish pharmaceutical parallel export market
5.28.2 Spanish pharmaceutical industry payments, 1999
5.28.3 R&D investment in Spain, 2000�2004
5.28.4 R&D investment in Spain, 1998
5.28.5 Spanish pharmaceutical market sales, 1997�1999
5.28.6 Spanish generics market
5.28.7 Pharmaceutical expenditure by therapeutic category, 1999
5.28.8 Effect of Spanish reference pricing system on pharmaceutical sales
5.28.9 Spanish pharmaceutical expenditure by region, 1999
5.28.10 Inappropriate prescribing of antibiotics in Spain
5.28.10.1 Catalan study
5.28.11 Catalan generic promotion study
5.28.12 New product approvals in Spain, 1999
5.28.13 Incidence of antibiotic use in Spain
5.28.14 Incidence of abortions in Spain, 1998
5.29 Sweden
5.29.1 Swedish pharmaceutical expenditure, 1999
5.29.2 Swedish market growth, 1999
5.29.3 Beta-interferon treatment costs in Sweden
5.29.4 Swedish pharmaceutical exports, 1999
5.29.5 Swedish Medical Products Agency's fees
5.30 Switzerland
5.30.1 Pharma approvals in Switzerland, 1999
5.30.2 Swiss pharmaceutical market, 1999
5.31 The Netherlands
5.31.1 Biotech funding in the Netherlands, 2000�2005
5.31.2 Pharmaceutical spending, 2001
5.31.3 Adverse drug reactions reported in 1999
5.32 United Kingdom
5.32.1 UK pharmaceutical trade, 1999
5.32.2 UK pharmaceutical imports, 1999
5.32.3 UK DTC advertising survey
5.32.4 UK pharmaceutical trade surplus
5.32.5 UK biotechnology sector
5.32.6 UK biotech sector fund raising, 2000
5.32.7 Additional DTI funding for UK biotech
5.32.8 Pharmaceutical company R&D investment in the UK, 1999
5.32.9 Highlights of UK manufacturing and R&D investment, 1999
5.32.10 UK-based pharmaceutical industry R&D investment, 1998
5.32.11 Number of UK marketing applications
5.32.12 UK OTC market, 1999
5.32.13 UK Pharmaton sales, 1999
5.32.14 UK Medicines Control Agency fees, 2000
5.32.15 Government investment in science research
5.32.16 Funding for prostate cancer research
5.32.17 UK government research expenditure, 2001�2003
5.32.18 UK funding for cancer and heart disease
5.32.19 UK funding for HIV/AIDS
5.32.20 Generic prescribing
5.32.21 NHS expenditure
5.32.21.1 Cost of adverse events to NHS
5.32.21.2 GP consultations for minor ailments
5.32.21.3 Per capita pharmaceutical expenditure in London
5.32.21.4 Proportion of NHS spend on Category D products, 1998�1999
5.32.21.5 NHS expenditure in England, 1998/99
5.32.21.6 NHS pharmaceutical expenditure, 1999
5.32.21.7 UK spend on specific therapeutic areas
5.32.21.8 NHS expenditure for cancer and heart disease, 2000�2003/04
5.32.22 National Health Service funding, 2000�2004
5.32.23 IT funding for NHS
5.32.24 Prescriptions
5.32.24.1 Prescription levels and costs in England, 1999
5.32.24.2 NHS prescription charges, 2000
5.32.24.3 Oral contraceptive prescription levels, 2000
5.32.24.4 Emergency contraception prescription
5.32.24.5 Average prescription costs in England, 1999
5.32.24.6 Prescription costs for PPIs: England 1999
5.32.24.7 Cost of prescribing Propecia on NHS
5.32.24.8 Methylphenidate prescribing
5.32.24.9 Cost of Avandia as an insulin substitute
5.32.24.10 Anti-lipid drug use in England
5.32.24.11 UK spend on antipsychotics
5.32.25 Alimentary/Metabolic
5.32.25.1 Prevalence of diabetes in the UK
5.32.26 Blood & clotting
5.32.26.1 Incidence of thalassaemia in the UK
5.32.27 Cardiovascular
5.32.27.1 UK incidence of heart attacks
5.32.27.2 Incidence of angina and myocardial infarction, England and Wales
5.32.28 Cancer
5.32.28.1 Cancer statistics for the UK
5.32.28.2 Prevalence of testicular cancer in the UK
5.32.28.3 UK breast cancer mortality rates, 1950 - 2000
5.32.28.4 Prostate cancer
5.32.28.5 UK ovarian cancer mortality rate
5.32.29 Cardiovascular
5.32.29.1 UK prevalence of angina and heart attacks
5.32.30 Genetic disorders
5.32.30.1 UK incidence of porphyria
5.32.31 Infectious diseases
5.32.31.1 Incidence of tuberculosis in the UK
5.32.31.2 Tuberculosis vaccination shortages
5.32.31.3 UK influenza vaccination rates 1999/2000
5.32.31.4 Incidence of bacteraemia in England and Wales, 1998
5.32.31.5 Prevalence of MRSA in UK hospitals
5.32.31.6 Group C meningitis mortality rate, 1998
5.32.31.7 Diphtheria vaccination
5.32.31.8 Hepatitis C
5.32.31.9 Incidence of pneumococcal pneumonia
5.32.32 Immunological
5.32.32.1 Incidence of AIDS/HIV in the UK
5.32.33 Musculoskeletal
5.32.33.1 Arthritis
5.32.34 Neurological
5.32.34.1 Incidence of cerebral palsy in the UK
5.32.34.2 Prevalence of migraine in the UK
5.32.34.3 Paracetamol usage
5.32.34.4 SSRI and atypical antipsychotic usage in England
5.32.35 Respiratory
5.32.35.1 Prevalence of asthma and hayfever
5.32.36 Sensory
5.32.36.1 Age-related macular degeneration
FAR EAST
5.33 China
5.33.1 Shanghai state pharma sector sales
5.33.2 Chinese imported pharmaceutical market, 1999
5.33.3 Pharmaceutical imports
5.33.4 Traditional Chinese medicines export market, 1999
5.33.5 Foreign investment: pharmaceutical companys' performance in China, 1999
5.33.6 Pharmaceutical expenditure in China, 1999
5.33.7 Pharmaceutical price cuts in China, 1999
5.33.8 Chinese biotech pharmaceutical market
5.33.9 Chinese pharmaceutical sales forecast, 2000
5.33.10 Chinese anticancer drug market, 1999�2006
5.33.11 Chinese diabetes market, 1998
5.33.12 Chinese oral antidiabetic market
5.33.13 Prevalence of benign prostatic hyperplasia in China
5.33.14 Prevalence of cancer in China
5.33.15 Prevalence of diabetes in China
5.33.16 Polio vaccination campaign
5.34 Japan
5.34.1 Japanese OTC market, 1998/99
5.34.2 Japanese biotech pharmaceutical market
5.34.3 Japanese antiviral market, 2000
5.34.4 Japanese fungal infection market
5.34.5 Market share of European companies in Japan
5.34.6 Life sciences promotion in Japan, 2000
5.34.7 Japanese price cuts, 2000
5.34.8 Impact of Japanese price cuts
5.34.9 Japanese pharmaceutical production, 1998
5.34.10 Japanese patent applications, 1998
5.34.11 Japanese blockbuster products
5.34.12 Financial results for leading Japanese companies, year ended March 2000
5.34.13 First-half results for leading Japanese companies
5.34.14 Abortion rates in Japan
5.34.15 Hepatitis B carrier levels in Japan
5.34.16 HIV-positive/AIDS situation in Japan, 1999
5.34.17 Incidence of B-cell lymphoma in Japan
5.34.18 Incidence of elevated cholesterol levels in Japan
5.34.19 Incidence of epilepsy
5.34.20 Incidence of erectile dysfunction in Japan
5.34.21 Incidence of HTVL-1 associated myelopathy in Japan
5.34.22 Incidence of influenza related mortality in Japan, 1999
5.34.23 Incidence of metastatic breast cancer in Japan
5.34.24 Oral contraception in Japan
5.34.25 Prevalence of allergic rhinitis
5.34.26 Prevalence of Alzheimer's disease in Japan
5.34.27 Prevalence of type 2 diabetes in Japan
5.35 Malaysia
5.35.1 Malaysian ADR reports
5.35.2 Prevalence of HIV in Malaysia
5.36 Nepal
5.36.1 Pharmaceutical importing in Nepal
5.37 Philippines
5.37.1 Pharmaceutical price cuts in The Philippines, 2000�2002
5.38 Singapore
5.38.1 Biotechnology investment in Singapore, 1998�2000
5.38.2 Life sciences sector funding
5.39 South Korea
5.39.1 Biotechnology funding in South Korea, 2000
5.39.2 Funding for pharmaceutical and medical research in South Korea, 2000�2010
5.39.3 South Korean healthcare market forecasts
5.39.4 Pharmaceutical sales in South Korea, 1998
5.39.5 Sales of the top 10 foreign affiliates in South Korea, 1999
5.39.6 South Korean pharmaceutical imports, 1999
5.39.7 Pharmaceutical turnover and profit in South Korea, 1998�1999
5.39.8 Prevalence of HIV in South Korea
5.40 Taiwan
5.40.1 Biotechnology sector development in Taiwan , 2000�2005
5.40.2 Taiwanese market growth, 1999
5.41 Vietnam
5.41.1 Vietnamese import expenditure, 1999
5.41.2 Elimination of trachoma in Vietnam
NEAR & MIDDLE EAST
5.42 Bangladesh
5.42.1 Healthcare improvements in Bangladesh
5.43 Bhutan
5.43.1 Commercialisation of traditional medicines
5.44 India
5.44.1 Indian pharmaceutical industry growth, 1998�1999
5.44.2 R&D in India, 1999/2000
5.44.3 Indian product launches, 1999
5.44.4 R&D promotion
5.44.5 Indian pharmaceutical manufacturing
5.44.6 Clinical trial applications, 2000
5.44.7 World Bank loans for health-related projects in India
5.44.8 Pharmaceutical trade between India and Namibia
5.44.9 Value of Indian antidiabetic market
5.44.10 Hepatitis mortality in India
5.44.11 Prevalence of tuberculosis in India
5.45 Iran
5.45.1 Domestic pharmaceutical production in Iran
5.45.2 Pharmaceutical sales in Iran, year ended March 2000
5.45.3 Leading pharmaceutical companies in Iran
5.46 Jordan
5.46.1 Pharmaceutical consumption in Jordan
5.47 Kazakhstan
5.47.1 Healthcare trends in Kazakhstan, 1999
5.48 Syria
5.48.1 Syrian pharmaceutical market
RUSSIA AND THE FORMER SOVIET REPUBLIC
5.49 Russia
5.49.1 Biotechnology industry output in Russia, 1999
5.49.2 Russian pharmaceutical company production
5.49.3 Russian pharmaceutical imports, (9 months) 2000
5.49.4 Pharmaceutical reimbursement budget for Moscow
5.49.5 Russian pharmaceutical industry growth forecast
5.49.6 Russian market value forecast, 2000
5.49.7 Pharmaceutical sales, 1st quarter 2000
5.49.8 Incidence of HIV in Russia
5.50 Lithuania
5.50.1 Funding of Lithuanian healthcare reforms
5.51 Ukraine
5.51.1 Ukraine health expenditure, 1998�1999
5.51.2 The Association of International Pharmaceutical Manufacturers in Ukraine
5.51.3 Ukraine pharmaceutical market
NORTH AMERICA
5.52 Canada
5.52.1 Canadian patented pharmaceutical market, 1998�1999
5.52.2 Canadian R&D expenditure
5.52.3 Canadian and US pharmaceutical price comparisons
5.52.4 Canadian Networks for Centres of Excellence programme budget, 1999�2002
5.52.5 Research funding in Canada
5.52.6 Medical research funding in Ontario
5.52.7 Healthcare expenditure in Ontario, 2000/01
5.52.8 Funding for genetic screening in Ontario
5.52.9 Canadian healthcare expenditure, 1999
5.52.10 Pharmaceutical expenditure in Ontario, 1992�1998
5.52.11 Council of Atlantic premiers
5.52.12 Patented approvals in Canada, 1999
5.52.13 New active substances approved in Canada, 1999
5.52.14 Federal research funding grants, 2000
5.52.15 Healthcare funding, 2000�2005
5.52.16 Cancer funding in Ontario
5.52.17 Bladder cancer
5.52.18 Incidence of chronic fatigue immune deficiency syndrome in Canada
5.52.19 Prevalence of hepatitis C in British Columbia
5.53 United States of America
5.53.1 US pharmaceutical sales forecast, 2000
5.53.2 Online pharmaceutical sales in the US
5.53.3 US prescription pharmaceutical market, 1999�2000
5.53.4 US mailed prescription market, 1999
5.53.5 US pharmaceutical company rankings
5.53.6 Top 20 US pharmaceutical products
5.53.7 US sales of selected 1998 launched products
5.53.8 Value of US functional foods market
5.53.9 Estimated sales for gatifloxacin in the US
5.53.10 US direct-to-consumer advertising expenditure, 1999
5.53.11 US DTC advertising expenditure, (6 months) 2000
5.53.12 US R&D expenditure, 2000
5.53.13 US biotech drug development
5.53.14 US pharmaceutical promotional expenditure, 1999
5.53.15 Number of biotech companies in the US, 1999
5.53.16 Major US companies' R&D expenditure
5.53.17 US shares data
5.53.18 Fortune 500 listings, 2000
5.53.19 US biotech share values, 1999
5.53.20 US NIH licensing royalties, 1993�2000
5.53.21 FDA approvals in 1999
5.53.22 FDA budget increases for 2001
5.53.23 Incidence of healthcare related preventable injury in the US
5.53.24 US prescription pharmaceutical expenditure, 1999�2004
5.53.25 US retail prescription market, 1999
5.53.26 Increasing US drug costs
5.53.27 Alimentary/Metabolic
5.53.27.1 Cholesterol levels in the US population
5.53.27.2 Diabetic patients taking Avandia
5.53.27.3 Prevalence of gastroparesis in diabetics in the US
5.53.27.4 Prevalence of foot ulcers in diabetics in the US
5.53.27.5 Incidence of familial adenomatous polyposis in the US
5.53.27.6 Incidence of irritable bowel syndrome
5.53.27.7 Inflammatory bowel disorder
5.53.27.8 Prevalence of liver disease in the US
5.53.27.9 Campylobacter diarrhoea
5.53.28 Blood & Clotting
5.53.28.1 Annual US incidence of meningococcaemia
5.53.28.2 Incidence of haemophilia in the US
5.53.28.3 Incidence of heparin-induced thrombocytopenia
5.53.28.4 Incidence of septic shock in the US
5.53.29 Cardiovascular
5.53.29.1 Incidence of angioplasties in the US
5.53.29.2 Incidence of cardiac surgery in infants in the US
5.53.29.3 Unstable angina
5.53.30 Dermatological
5.53.30.1 Atopic dermatitis
5.53.31 Genetic
5.53.31.1 Prader-Willi syndrome
5.53.32 Hormonal
5.53.32.1 US conjugated oestrogen market
5.53.33 Immunological
5.53.33.1 Neoral market share, 1999/2000
5.53.33.2 Prevalence of Sj�gren's syndrome in the US
5.53.34 Infectious
5.53.34.1 Hepatitis C mortality rate in the US
5.53.34.2 Herpes virus carriers
5.53.34.3 Hospital acquired pneumonia
5.53.34.4 Incidence of Clostridium difficile infections in US
5.53.34.5 Incidence of otis media
5.53.34.6 Incidence of Streptococcus pneumoniae infection in the US
5.53.34.7 Incidence of syphilis, 1997�1998
5.53.34.8 Market value of mycobacterial infections
5.53.34.9 Prevalance of pneumococcal bacteraemia
5.53.34.10 Prevalence of genital warts in the US
5.53.35 Musculoskeletal
5.53.35.1 Incidence of osteopetrosis in the US
5.53.35.2 Incidence of male osteoporosis
5.53.35.3 Prevalence of osteoarthritis in the US
5.53.35.4 Prescription levels for COX-2 inhibitors and NSAIDs, 1999
5.53.36 Neurological
5.53.36.1 Incidence of neuropathic pain in the US
5.53.36.2 Prevalence of multiple sclerosis
5.53.36.3 Prevalence of Alzheimer's disease in the US
5.53.36.4 Prevalence of generalised anxiety disorder in Americans
5.53.36.5 Prevalence of narcolepsy in the US
5.53.36.6 Prevalence of stroke
5.53.36.7 Schizophrenia
5.53.36.8 Sleep disorder prevalence in the US
5.53.36.9 US market for attention-deficit hyperactivity disorder, 1999
5.53.37 Paediatric
5.53.37.1 Incidence of apnoea of prematurity
5.53.37.2 Incidence of meconium aspiration syndrome in the US
5.53.37.3 Paediatric antidepressant use
5.53.38 Respiratory
5.53.38.1 Prevalence of asthma in the US
5.53.38.2 Prevalence of pulmonary fibrosis
5.53.39 Miscellaneous
5.53.39.1 Incidence of Beh�et's disease in the US
SOUTH AND CENTRAL AMERICA
5.54 Argentina
5.54.1 Argentinian pharmaceutical market, 1999
5.55 Brazil
5.55.1 Antiretroviral treatment costs in Brazil, 1996�2000
5.55.2 Pharmaceutical sales in Brazil, January � July 2000
5.55.3 Brazilian pharmaceutical expenditure
5.55.4 Brazilian government price controls
5.55.5 Restriction of antibiotics sales in Brazil
5.55.6 Issue of healthcare cards in Brazil
5.55.7 Brazilian healthcare funding increase
5.55.8 Brazil's anti-AIDS policies
5.55.9 Brazilian company news round up
5.55.9.1 New products launched in Brazil
5.55.10 Reluctance over generics in Brazil
5.55.11 Frequency of thyroglobulin testing in Brazil
5.55.12 Brazilian sales of Viagra, 1999
5.55.13 Malaria situation in Brazil, 1998�2000
5.55.14 Incidence of HIV-positive women giving birth
5.56 Ecuador
5.56.1 Pharmaceutical sales in Ecuador, 1999
5.57 Guatemala
5.57.1 Guatemalan vaccination programme

SECTION 6 THERAPEUTIC
6.1 Alimentary/Metabolic
6.1.1 Angioedema
6.1.2 Barrett's oesophagus
6.1.3 Diabetes
6.1.3.1 Definition of diabetes
6.1.3.2 Worldwide prevalence of diabetes
6.1.4 Erosive oesophagitis
6.1.5 Incidence of hereditary tyrosinaemia Type I in the US and Canada
6.1.6 Pancreatic insufficiency treatment market
6.1.7 Prevalence of gastrointestinal motility problems in the US and Europe
6.2 Blood & Clotting
6.2.1 Haemophilia A
6.3 Cancer
6.3.1 Definition of cancer
6.3.2 Actinic keratosis
6.3.3 Breast cancer
6.3.4 Cancer pain
6.3.5 Colon cancer
6.3.6 Colorectal cancer
6.3.7 Head and neck cancer
6.3.8 Leukaemia
6.3.8.1 Definition of leukaemia
6.3.8.2 Acute myeloid leukaemia
6.3.8.3 Acute promyelocytic leukaemia
6.3.8.4 Cutaneous T-cell lymphoma
6.3.8.5 Chronic myelocytic leukeamia
6.3.8.6 Refractory chronic lymphocytic leukaemia
6.3.9 Lymphoma
6.3.10 Lung cancer
6.3.11 Prostate cancer
6.3.12 Testicular cancer
6.4 Cardiovascular
6.4.1 ACE-inhibitors
6.4.2 Angioplasty
6.4.3 Decompensated heart failure
6.4.4 Ischaemic heart disease
6.4.5 Pulmonary hypertension
6.4.6 Sudden cardiac death
6.4.7 Worldwide mortality rate for coronary heart disease
6.5 Genetic disorders
6.5.1 Fabry disease
6.5.2 Familial hypercholesterolaemia
6.5.3 Gaucher's disease
6.5.4 Lipodystrophy
6.5.5 Pompe disease
6.5.6 X-linked severe combined immunodeficiency
6.6 Genitourinary
6.6.1 Haemolytic uraemic syndrome
6.6.2 Prevalence of erectile dysfunction in Europe
6.6.3 Prevalence of polycystic ovarian syndrome in Japan and the US
6.7 Genetic
6.7.1 Duchenne muscular dystrophy
6.8 Hormonal
6.8.1 Acromegaly
6.8.2 Infertility
6.8.3 Premenstral dysmorphic disorder
6.9 Immunological
6.9.1 Chronic fatigue syndrome
6.9.2 Common variable immunodeficiency
6.9.3 HIV/AIDS
6.9.3.1 Impact of HIV
6.9.3.2 Incidence of HIV infection in infants
6.9.3.3 Worldwide prevalence of HIV
6.9.3.4 HIV/AIDS epidemic continues to grow
6.9.3.5 Incidence of cryptococcal menigitis in AIDS patients
6.9.3.6 Incidence of oesophageal candidiasis in HIV/AIDS patients
6.9.4 Scleroderma
6.9.5 Worldwide and US prevalence of systemic lupus erythematosus
6.10 Infectious diseases
6.10.1 Diarrhoea mortality levels in developing countries
6.10.2 Hepatitis B
6.10.3 Hepatitis C
6.10.4 Immunisation in poor countries
6.10.5 Incidence of verotoxigenic Escherichia coli infection in the Benelux region
6.10.6 Malaria
6.10.7 Measles
6.10.8 Polio eradication
6.10.9 Prevalence of Campylobacter infection
6.10.10 Prevalence of cerebral malaria in sub-Saharan Africa
6.10.11 Prevalence of dengue fever
6.10.12 Prevalence of lymphatic filariasis
6.10.13 Prevalence of meningitis C in the US and the UK
6.10.14 Sepsis
6.10.15 West Nile encephalitis
6.11 Musculoskeletal
6.11.1 Osteoporosis
6.11.1.1 Male osteoporosis
6.11.2 Pompe's disease
6.11.3 Rheumatoid arthritis
6.11.3.1 Prevalence of rheumatoid arthritis in Europe
6.11.4 Cervical dystonia
6.12 Neurological
6.12.1 Neurogenic pain
6.12.2 Prevalence of late-stage Parkinson's disease in the US and Europe
6.12.3 Prevalence of smoking and smoking related mortality in Europe
6.12.4 Primary progressive multiple sclerosis
6.12.5 Relapsing-remitting multiple sclerosis
6.13 Parasitic
6.13.1 Prevalence of Guinea worm disease
6.13.2 Prevalence of leishmaniasis
6.13.3 Schistosomiasis
6.14 Respiratory
6.14.1 Alpha1-antitrypsin deficiency
6.14.2 Chronic obstructive pulmonary disease
6.14.3 Market for asthma and rhinitis
6.14.4 Market value of loratadine
6.14.5 Prevalence of tuberculosis
6.15 Sensory
6.15.1 Age-related macular degeneration
6.15.2 Ocular histoplasmosis syndrome

SECTION 7 CLINICAL TRIALS
7.1 Clinical Trials for Alimentary/Metabolic Indications
7.1.1 Anti-obesity
7.1.2 Barrett's oesophagus
7.1.3 Chronic constipation
7.1.4 Fabry disease
7.1.5 Familial adenomatous polyposis
7.1.6 Glaxo Wellcome's new oral antidiabetic
7.1.7 Humanised monoclonal antibody treatment for ulcerative colitis
7.1.8 Infliximab in Crohn's disease
7.1.9 Irritable bowel syndrome
7.1.10 Losec for bleeding peptic ulcers
7.1.12 Xenical benefit in diabetes
7.2 Clinical trials for anti-infectives
7.2.1 Antibiotics
7.2.1.1 Oxazolidinones
7.2.1.2 Ketolides
7.2.2 Helicobacter pylori
7.2.3 Hepatitis C
7.2.4 Relenza trials
7.2.5 Sepsis
7.3 Clinical Trials for Blood & Clotting Indications
7.3.1 Combining low-molecular weight heparins with antiplatelet drugs
7.3.2 Fragmin for the prevention of deep vein thrombosis
7.3.3 Hemolink
7.3.4 Unfractioned heparin versus low-molecular weight heparin
7.3.5 Venous thromboembolism
7.4 Clinical Trials for Cancer Indications
7.4.1 Acute myeloid leukaemia
7.4.2 Acute promyelocytic leukaemia
7.4.3 Bone metastases
7.4.4 Breast cancer
7.4.5 Colorectal cancer
7.4.6 Endometrial cancer
7.4.7 Head and neck cancer
7.4.8 Liver cancer
7.4.9 Lung cancer
7.4.9.1 Non small-cell lung cancer
7.4.9.2 Small-cell lung cancer
7.4.10 Malignant melanoma
7.4.11 Non-Hodgkin's lymphoma
7.4.12 Ovarian cancer
7.4.12.1 Hycamtin as first-line therapy
7.4.13 Prostate cancer
7.4.14 Tumour necrosis factor
7.5 Clinical Trials for Cardiovascular Indications
7.5.1 Acute myocardial infarction
7.5.2 Cholesterol
7.5.2.1 Zocor versus Lipitor
7.5.2.2 Combination niacin/lovastatin hypolipaemic product development
7.5.2.3 Atherosclerosis in familial hypercholesterolaemia
7.5.2.4 Baycol as effective as Lipitor
7.5.3 Heart failure
7.5.3.1 ACE-inhibitors for heart failure
7.5.3.2 Carvedilol trial
7.5.3.3 Congestive heart failure
7.5.3.4 levosimendan
7.5.3.5 Vasopeptidase inhibitors
7.5.3.6 Valsartan for heart failure
7.5.4 Coronary heart disease
7.5.4.1 Coronary heart disease in diabetics
7.5.5 Hypertension
7.5.5.1 Calcium antagonists
7.5.6 Integrilin for angioplasty with stenting
7.5.7 Statin therapy
7.6 Clinical Trials for Dermatological Indications
7.6.1 Actinic keratoses
7.6.2 Artificial skin treatment
7.6.3 Eczema
7.6.4 Scalp dermatitis
7.6.5 Severe atopic dermatitis
7.6.6 Unwanted facial hair
7.7 Clinical Trials For Gene Therapy
7.7.1 Gene therapy for X-linked severe combined immunodeficiency
7.8 Clinical Trials For Genitourinary Indications
7.8.1 Benign prostatic hyperplasia
7.8.2 Erectile dysfunction
7.9 Clinical Trials For Hormonal Indications
7.9.1 Acromegaly
7.9.2 Contraceptives
7.9.2.1 Low-dose oral contraceptives
7.9.2.2 Male contraceptive pill
7.9.2.3 Emergency contraception
7.9.3 Hormone replacement therapy
7.9.3.1 Combination HRT
7.9.3.2 Low-dose HRT
7.9.4 Infertility treatment
7.9.5 Selective oestrogen receptor modulators
7.10 Clinical Trials For Immunological Indications
7.10.1 Immunosuppressants
7.10.1.1 Mycophenolate mofetil
7.10.1.2 Basiliximab
7.10.1.3 Lopinavir plus ritonavir
7.10.2 HIV/AIDS
7.10.3 Scleroderma
7.10.4 Systemic lupus erythematosus
7.10.5 Thalidomide
7.11 Clinical Trials For Musculoskeletal Indications
7.11.1 Rheumatoid arthritis
7.11.1.1 COX-2 inhibitors versus traditional NSAIDs in rheumatoid arthritis
7.11.1.2 Juvenile rheumatoid arthritis
7.11.2 Osteoporosis
7.11.2.1 Statins for osteoporosis
7.11.2.2 Male osteoporosis
7.11.3 Osteopetrosis
7.11.4 Pompe's disease
7.12 Clinical Trials For Neurological Indications
7.12.1 Alcoholism
7.12.2 Alzheimer's disease
7.12.3 Bipolar disorder (manic depression)
7.12.4 Epilepsy
7.12.5 Dysthymia and mild depression
7.12.6 Generalised anxiety disorder
7.12.7 HIV/AIDS-related anorexia
7.12.8 Insomnia
7.12.9 Multiple sclerosis
7.12.9.1 Secondary progressive multiple sclerosis
7.12.10 Pain
7.12.11 Parkinson's disease
7.12.12 Schizophrenia
7.12.13 Smoking cessation
7.12.14 Strokes
7.12.15 SSRIs for severe PMS
7.12.16 Statins for dementia
7.13 Clinical Trials For Paediatric Indications
7.13.1 Apnoea of prematurity
7.14 Clinical Trials For Anti-Parasitic Indications
7.14.1 Schistosomiasis
7.14.2 Sleeping sickness
7.15 Clinical Trials For Respiratory Indications
7.15.1 Asthma
7.15.2 Antihistamine sedation
7.15.2.1 Desloratadine � Claritin's active metabolite
7.15.3 Chronic obstructive pulmonary disease
7.15.4 Cystic fibrosis
7.15.5 Treatment of the common cold
7.16 Clinical Trials For Sensory Indications
7.16.1 Age-related macular degeneration
7.16.2 Classic subfoveal neovascularisation
7.16.3 Cytomegalovirus retinitis in HIV patients
7.16.4 Ocular hypertension
7.17 Vaccines
7.17.1 Yellow fever
7.17.2 Invasive pneumococcal disease
7.17.3 Herpes vaccine

INDEX

Executive Summary

The 17th edition of Scrip's Yearbook contains three new sections, covering e-commerce activities in the pharmaceutical industry, a summary of a selection of the Scrip Reports published during 2000 and an overview of clinical trial results organised by therapeutic indication.

The new section on e-commerce includes highlights of website launches that have been mentioned in Scrip during 2000, as well as an article reviewing a study on pharmaceutical purchasing via the Internet. E-commerce activities by specific countries and pharmaceutical companies are also included in this section, which gives an overview of Internet-based developments within the pharmaceutical industry during 2000.

Summaries of a selection of Scrip Reports have been brought together to form another new section of the 2001 Yearbook. These summaries provide an insight into the subjects covered in each report and deal with a diverse range of subject areas including women's healthcare, advances in pain management, gastrointestinal disorders, DTC advertising and mergers and acquisitions.

The third new section of the 2001 Yearbook contains results from clinical trials that have been published or presented in 2000 and subsequently reported in Scrip. The section includes results of a study comparing simvastatin (Merck & Co's Zocor) with atorvastatin (Pfizer's Lipitor), a comparison of calcium blockers with antihypertensives and the results of Phase III trials with Takeda/Abbott's Uprima (apomorphine) for erectile dysfunction.

As with previous editions of the Yearbook, there are also sections on country markets, industry data and details of the activities of the top 30 pharmaceutical companies, as well as disease statistics in the therapeutic section and an industry overview. In addition, for each country mentioned in the Yearbook there is also a table of socio-demographic data, detailing the size of the county's population, birth and death rates, employment levels, literacy levels and access to safe water and healthcare.

Pfizer and Warner-Lambert concluded the $90 billion merger on February 7th 2000, ending the three-way struggle with Warner-Lambert's original merger partner, American Home Products. The enlarged company, known as Pfizer, has expected annual revenues of about $28 billion, including $21 billion in pharmaceutical sales, and a market capitalisation of $230 billion. Revenues are expected to grow at an annual rate of 13% until 2003. Earnings growth is expected to increase 25% annually until 2002, helped by the planned $1.6 billion cost savings, more than 60% of which should be achieved by 2001.

The deal headed off a court battle between Warner-Lambert and Pfizer over their agreement for the cholesterol-lowering product, Lipitor (atorvastatin). This was set to begin on February 14th and had been a driving force in the negotiations. The companies had sued and counter-sued each other, with Warner-Lambert contending that by making a hostile bid, Pfizer jeopardised its rights to certain Lipitor profits.

Another significant event which is included in the Yearbook is the sale of BASF's pharmaceutical division, Knoll, to Abbott. Only a year ago BASF gave its pharmaceuticals division two years to shape up, but the sale to Abbott for $6.9 billion in cash came as no great shock to the industry. BASF had ordered the pharma business to bring its earnings before interest and tax up from around 5% of sales to the level of peer companies (15-20%), but in 1999, the unit only achieved earnings before special items of e175 million on sales of e2.5 billion. The sale is expected to be completed during the first quarter of 2001.